GlassScriptPhysician profile
Ajay Bajaj
NPI 1518943513
$75,576.46
in general payments reported to CMS, 2019-2025
55 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $4,559 · 2021: $4,744 · 2022: $7,904 · 2023: $12K · 2024: $9,158 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $15K · Consulting Fee: $3,830 · Travel and Lodging: $544 · Education: $31.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,825.00 |
| Food and Beverage | $15,475.14 |
| Consulting Fee | $3,830.00 |
| Travel and Lodging | $544.28 |
| Education | $31.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,218.35 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12,074.89 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Allergan, INC. | $11,433.75 | 2019-2020 | |
| Madrigal Pharmaceuticals | $3,938.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $3,656.86 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Ardelyx, INC. | $1,751.72 | 2023-2025 | Ibsrela |
| Endogastric Solutions, INC | $1,748.06 | 2019-2024 | Esophyx |
| Janssen Biotech, INC. | $1,286.47 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,086.81 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pinnacle Biologics, INC | $1,057.43 | 2024 | Photofrin |
| Ironwood Pharmaceuticals, INC | $938.93 | 2019-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $900.51 | 2021-2023 | |
| Genzyme Corporation | $831.09 | 2022-2025 | |
| Medtronic, INC. | $803.89 | 2021-2025 | Endoflip, Signia |
| Pfizer INC. | $787.90 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $688.66 | 2019-2024 | |
| Gilead Sciences, INC. | $642.97 | 2019-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $617.44 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $351.65 | 2021-2022 | |
| Boston Scientific Corporation | $315.10 | 2019-2023 | Spyglass Discover |
| Apollo Endosurgery US INC | $282.06 | 2019-2022 | |
| Lilly USA, LLC | $274.84 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $270.93 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $265.80 | 2025 | Zenpep, Vowst |
| Conmed Corporation | $243.68 | 2023-2024 | Conmed Hemostasis, Conmed Generators, Conmed Biliary |
| Intercept Pharmaceuticals, INC. | $243.47 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $235.88 | 2024-2025 | Terlivaz |
| Qol Medical, LLC | $166.66 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $140.85 | 2019-2024 | Dificid |
| Celgene Corporation | $128.90 | 2021-2024 | Zeposia |
| Lucid Diagnostics INC. | $117.21 | 2023 | |
| Novo Nordisk INC | $103.28 | 2025 | Wegovy |
| Shionogi INC | $98.54 | 2020 | |
| Janssen Scientific Affairs, LLC | $90.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.83 | 2023-2024 | Cyltezo |
| Ethicon US, LLC | $87.52 | 2020 | |
| Digestive Care, INC. | $81.58 | 2019 | |
| Ferring Pharmaceuticals INC. | $61.66 | 2023-2025 | Rebyota |
| Daiichi Sankyo INC. | $44.88 | 2023-2024 | Injectafer |
| Romark Laboratories, Lc | $43.59 | 2019-2020 | |
| Amgen INC. | $41.04 | 2023 | Amjevita |
| Orphalan INC | $37.42 | 2024-2025 | Cuvrior |
| Vivus LLC | $37.37 | 2025 | Pancreaze |
| Evoke Pharma, INC. | $36.51 | 2023 | Gimoti |
| Braintree Laboratories, INC. | $28.94 | 2025 | Suflave, Sutab |
| Micro-Tech Endoscopy USA, INC. | $26.58 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $24.27 | 2024 | Iqirvo |
| Biocon Biologics INC | $21.81 | 2024 | Hulio |
| Recordati_rare_diseases_inc. | $21.43 | 2025 | Panhematin |
| Ambu INC. | $21.10 | 2023 | |
| Alnylam Pharmaceuticals INC. | $17.72 | 2022 | |
| Mylan Institutional INC. | $17.04 | 2023 | Hulio |
| Organon LLC | $15.96 | 2023 | Renflexis |
| Celltrion USA INC. | $15.31 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $13.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.